Conserved Domains in Variable Surface Lipoproteins A-G of <i>Mycoplasma hyorhinis</i> May Serve as Probable Multi-Epitope Candidate Vaccine: Computational Reverse Vaccinology Approach

<i>Mycoplasma hyorhinis</i> (<i>M. hyorhinis</i>) is responsible for infections in the swine population. Such infections are usually cured by using antimicrobials and lead to develop resistance. Until now, there has been no effective vaccine to eradicate the disease. This stu...

Full description

Bibliographic Details
Main Authors: Muhammad Zubair, Jia Wang, Yanfei Yu, Muhammad Asif Rasheed, Muhammad Faisal, Ali Sobhy Dawood, Muhammad Ashraf, Guoqing Shao, Zhixin Feng, Qiyan Xiong
Format: Article
Language:English
Published: MDPI AG 2023-09-01
Series:Veterinary Sciences
Subjects:
Online Access:https://www.mdpi.com/2306-7381/10/9/557
Description
Summary:<i>Mycoplasma hyorhinis</i> (<i>M. hyorhinis</i>) is responsible for infections in the swine population. Such infections are usually cured by using antimicrobials and lead to develop resistance. Until now, there has been no effective vaccine to eradicate the disease. This study used conserved domains found in seven members of the variable lipoprotein (VlpA-G) family in order to design a multi-epitope candidate vaccine (MEV) against <i>M. hyorhinis</i>. The immunoinformatics approach was followed to predict epitopes, and a vaccine construct consisting of an adjuvant, two B cell epitopes, two HTL epitopes, and one CTL epitope was designed. The suitability of the vaccine construct was identified by its non-allergen, non-toxic, and antigenic nature. A molecular dynamic simulation was executed to assess the stability of the TLR2 docked structure. An immune simulation showed a high immune response toward the antigen. The protein sequence was reverse-translated, and codons were optimized to gain a high expression level in <i>E. coli</i>. The proposed vaccine construct may be a candidate for a multi-epitope vaccine. Experimental validation is required in future to test the safety and efficacy of the hypothetical candidate vaccine.
ISSN:2306-7381